He added: “Now is the time to act to protect people around the world from the threat posed by AMR.”
Estimates for the new study were produced for 22 pathogens (organisms that cause disease), 84 pathogen-drug combinations, and 11 infectious conditions (including meningitis, bloodstream infections and other infections) among people of all ages in 204 countries and territories.
The estimates were based on a wide range of sources, including hospital data, death records and antibiotic use data.
Study author Stein Emil Vollset, of the Norwegian Institute of Public Health and affiliate professor at IHME, said: “By 2050, resistant infections could be involved in some eight million deaths each year, either as the direct cause of death or as a contributing factor.
“To prevent this from becoming a deadly reality, we urgently need new strategies to decrease the risk of severe infections through vaccines, new drugs, improved healthcare, better access to existing antibiotics and guidance on how to use them most effectively.”
Colin Brown, deputy director at UKHSA responsible for AMR, said: “This report is another reminder that antibiotic resistance is a threat to all of us – not just in the future but now.
“If more infections continue to become resistant to treatment, lives will continue to be lost and we need universal action to turn this tide.
“We can all help by only taking antibiotics if you have been told to do so by a healthcare professional.
“Do not save some for later or share them with friends and family. Treat antibiotics with respect and they will be there to help us all in the future.”
The researchers estimate that AMR deaths will increase steadily in the coming decades, with 1.91 million annual deaths directly due to AMR projected by 2050 – a 67.5 per cent increase from the 1.14 million deaths in 2021.
By the middle of the century, AMR is also projected to play a role in a broader 8.22 million deaths – an increase of 74.5 per cent from the 4.71 million associated deaths in 2021.
The World Health Organisation (WHO) has described AMR as “one of the top global public health and development threats”.
The new research suggests that future deaths from AMR will be highest in south Asia – which includes countries such as India, Pakistan, and Bangladesh – where a total of 11.8 million deaths directly due to AMR are forecast between 2025 and 2050.
In a separate comment piece, also published in The Lancet, experts have warned that without immediate action, humanity will face a potentially disastrous escalation in resistance in fungal disease.
The piece was coordinated by scientists at the University of Manchester, the Westerdijk Institute and the University of Amsterdam.
According to the scientists, most fungal pathogens identified by the WHO – accounting for around 3.8 million deaths a year – are either already resistant or rapidly acquiring resistance to antifungal drugs.
Norman van Rhijn, from the University of Manchester, said: “Most people agree that resistant bacterial infections constitute a significant part of the AMR problem.
“However, many drug resistance problems over the past decades have also been the result of invasive fungal diseases largely under recognised by scientists, governments, clinicians and pharmaceutical companies.
“The threat of fungal pathogens and antifungal resistance, even though it is a growing global issue, is being left out of the debate.”
Elsewhere, scientists led by a team of researchers at the University of Cambridge say monoclonal antibodies – treatments developed by cloning a cell that makes an antibody – could help provide an answer to AMR.
They have developed a monoclonal antibody drug, using a technique involving genetically engineered mice.
In the study published in Nature Communications, the team was able to show that these monoclonal antibodies were able to prevent infection with Acinetobacter baumannii, a bacteria associated with hospital-acquired infections.
More work is now needed to understand the mechanism by which the drug protects against infection, as this could allow the team to develop an even more effective treatment.
